What happens when you compare #ShockwaveIVL# head-to-head with atherectomy in the real world? The results speak for themselves. With 1,005 patients, the ROLLING-STONE Registry is the largest prospective, multicenter study to include a head-to-head comparison of #ShockwaveIVL# and atherectomy in a real-world, all-comers population. The study confirmed strong procedural success and intraprocedural safety with Shockwave IVL. It also demonstrated a favorable 30-day MACE rate and a significantly lower 1-year MACE after propensity score matching compared with atherectomy. Read the full summary:  US Rx only. Safety Info:  Product availability may vary by country.

🧈 “Delivered like a hot knife through butter.” Hear Dr. Jeff Tyler share how he treated a late-70s male patient with a history of heart failure, angina, and low EF using the new Shockwave C2 Aero catheter. In this case, Shockwave Coronary IVL was used to address a heavily calcified LAD lesion and support optimal stent delivery and expansion. US Rx only.​ Safety Info link in Bio. Product availability may vary by country.

#ShockwaveIVL’s# clinical evidence is different. Our predictably safe and consistently effective MOA has been validated by nearly 25,000 published patient outcomes across more than 600 scientific publications. To date, we have supported more than 70 company-led and investigator-initiated clinical studies, with an additional 50 planned between 2025 and 2029. Each study is designed to reflect the complex scenarios physicians encounter every day and to generate the clinical evidence needed to support confident adoption of Shockwave IVL. Read this new Cardiac Interventions Today article by our CMO, Nick West, to learn what our relentless commitment to research means for the future of calcium modification:  US Rx only. Safety Info:  availability may vary by country.

For International Audiences: Patients with diabetes often represent a more complex population, but REDUCER I showed that #ShockwaveReducer# delivers angina relief equally for patients suffering from diabetes.​ The trial demonstrated that device implantation was safe and just as effective at improving angina symptoms and quality of life in patients with and without diabetes.​ Explore the REDUCER I Diabetes Sub-Analysis:  de Silva, R. Results from the REDUCER-I Study. ESC 2025​ Safety Info: ​ CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.

Designed specifically for the challenges of BTK heavily calcified peripheral artery disease, #ShockwaveJavelin# modifies calcium to create a small lumen which enables further therapy to restore inline flow. Learn how this device fits into BTK interventional workflows by reading two successful case reports from Charles Bailey, MD, George Adams, MD and Vanessa Adams, BS in this Vascular Specialist article: Charles Bailey and George Adams are paid consultants of Shockwave Medical. US Rx only. Safety Info: Product availability may vary by country.

For International Audiences: The REDUCER I trial demonstrated #ShockwaveReducer#'s real-world impact on patients, with the following benefits at one year:​ ➡️ 66% decrease in total number of emergency department visits in the year after implantation​ ➡️ 71% ≥1 CCS improvement ​ ➡️ 26% ≥2 CCS improvement​ Learn more: Watch the study's lead investigator, Dr Stefan Verheye, discuss the 12-month results: Verheye S. et al. European Heart Journal. (2024) Vol 45 (Suppl 1)​ Safety info link in Bio. CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.

When no balloon or microcatheter could initially track heavily calcified BTA vessels, Dr Manolo Rubio enlisted the help of #ShockwaveJavelin#. In an @EVToday article, he describes how impactful this new device has been for enabling treatment, restoring flow and promoting wound healing in patients suffering from complex CLTI disease. Read more about his experiences and dive into a DPA CTO case spotlight here: Featured physicians are paid consultants of Shockwave Medical. US Rx only. Safety Info:  availability may vary by country.

Thrilled to announce the first SKYWARD IDE enrollment! Huge congratulations to Dr @NickMouawadMD & team at McLaren Bay Region Hospital in Bay City, MI on enrolling the first patient in the clinical program to evaluate the novel Shockwave SkyRunner Carotid IVL System for the treatment of calcified carotid arteries prior to stenting.  Read the Press Release:   CAUTION - Investigational device. Limited by US law to investigational use.

SKYWARD is off and running! Johnson & Johnson announced today the initiation of its SKYWARD IDE clinical program evaluating the novel Shockwave SkyRunner Carotid IVL System for the treatment of calcified carotid arteries prior to stenting. This clinical program is part of Johnson & Johnson’s plan to enhance treatment options for patients with calcified carotid artery disease, which accounts for up to one-third of all strokes. Read the Press Release: @JNJNews @JNJMedTech @NickMouawadMD CAUTION - Investigational device. Limited by US law to investigational use.

For International Audiences: COSIRA was the first randomized sham-controlled trial studying the use of #ShockwaveReducer# for refractory angina.​ This pivotal trial demonstrated that patients who received Shockwave Reducer achieved a statistically significant improvement in angina symptoms and quality of life compared to patients in the sham control group. ​ Explore the COSIRA results:  Verheye S. et al. Coronary sinus reducer for treatment of refractory angina: the COSIRA trial. N Engl J Med. 2015;372:519-27.​ Safety Info: ​ CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.

For Healthcare Professionals Only: Dziękuję, Poland! What inspiring days of clinical exchange. Last week, our latest device made its debut at the 2nd Kashubian-Pomeranian Interventional Cardiology Workshop, bringing together a highly engaged community of interventional cardiologists. The first clinical use, led by Dr. Michał Hawranek (@HawranekMichal), lays the groundwork for the rapid adoption of next‑generation #ShockwaveIVL# technologies in Poland and further progress in calcium modification. It was a pleasure to connect and exchange valuable perspectives on how this innovation can support daily practice and advance calcium modification. Together, we’re shaping what’s next in calcium treatment. For professional use only. US Rx only. Safety Info: Product availability may vary by country.

Safety is in our DNA and MOA. #ShockwaveIVL# delivers shockwaves that crack hard calcium without damaging soft tissue — the product of nearly a decade spent refining extracorporeal lithotripsy principles into a purpose-built vascular solution. The combination of Shockwave's acoustic waveform and energy delivery is what makes Shockwave IVL predictable safe and consistently effective. Learn more about our proven MOA by reading our CMO Nick West’s latest article in @CardiacInterv:  US Rx only. Safety Info: availability may vary by country.

Congratulations to Dr. William Crowder, Dr. Russell Young, and the Jackson Heart Clinic team on their participation in the COSIRA-II study. With their first randomized controlled trial (RCT) enrollment at FMOL Health | St. Dominic Hospital (@stdominichealth), they join the growing network of #COSIRAII# enrolling sites. This milestone marks the first case at both their hospital and in the state of Mississippi! 🎉 Interested in learning more about the COSIRA-II trial and participating sites? Visit Safety Info: CAUTION: Investigational Device. Limited by U.S. [and Canadian law] to investigational use.

See how #ShockwaveJavelin# can spark better BTK interventions by diving into two #PeripheralIVL# case reviews recently published in Vascular Specialist. Charles Bailey, MD, George Adams, MD and Vanessa Adams, BS, describe in-depth how Shockwave Javelin successfully enabled treatment of heavily calcified BTK vessels, including distal tibial and pedal lesions. Read the article today:  Charles Bailey and George Adams are paid consultants of Shockwave Medical. US Rx only. Safety Info: Product availability may vary by country.

For International Audiences: Angina treatment that's proven to provide relief. The ORBITA-COSMIC RCT showed that #ShockwaveReducer# improved angina symptoms and quality of life compared to placebo. Dig into the results to learn more.​ Angina relief is here. See the proof:  Foley MJ, Rajkumar CA, Ahmed‑Jushuf F, et al. Coronary sinus Reducer for the treatment of refractory angina (ORBITA‑COSMIC): a randomized, placebo‑controlled trial. Lancet. 2024;403(10436):1543‑1553.​ ​ Safety Info: ​ CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.

Muchas gracias CITIC2026! Once again, @CiticMexico proved to be a leading international forum in cardiovascular interventions and an ideal platform for #ShockwaveIVL# to share its MOA and showcase its technology. Thank you to all physicians and attendees who joined our sessions and contributed to valuable discussions on the management of complex coronary calcium. @aadilshaukat34 @McInerneyAngela Presenting physicians are paid consultants of Shockwave Medical. US Rx only. Safety Info: ​Product availability may vary by country.

#ShockwaveC2Aero# continues to make waves across Northern UK and Ireland! With improved deliverability and a fast procedural flow, Shockwave C2 Aero is designed to reach and treat even the most challenging calcified coronary lesions. These first cases mark more than a launch milestone. They reflect #ShockwaveIVL’s# commitment to innovation and serve as a powerful reminder of what innovation is truly for, making complex care more achievable, consistent, and patient centered. We're proud to stand alongside UK and Irish interventional cardiologists in tackling complex coronary calcium. US Rx only. Safety Info: ​ Product availability may vary by country.

In a new Vascular Specialist article, Charles Bailey, MD, George Adams, MD and Vanessa Adams, BS, discuss how #ShockwaveJavelin# effectively enabled further treatment for patients suffering from CLTI. Two real-world case reviews crack into the details of these successful BTK interventions — read them now: Charles Bailey and George Adams are paid consultants of Shockwave Medical. US Rx only. Safety Info: Product availability may vary by country.

For International Physicians: Refractory angina is often not the end of the road. It’s about understanding the underlying mechanisms and identifying patients who do have new therapeutic options. Despite optimal therapy, many patients continue to experience debilitating symptoms. Innovative approaches like the #ShockwaveReducer# are helping redefine what’s possible. This was a key theme in the discussion between Dr Tim van de Hoef (@drTPH) and Dr Tommaso Gori (@tommasoggori) at EuroPCR 2026, highlighting the importance of better patient identification and how a shift in perspective can open new possibilities, including the #ShockwaveReducer#. Watch the video to explore how the understanding of refractory angina is evolving and why it may not be as “refractory” as we think: Safety info link in Bio. CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.

🚀 First case. New possibilities. #ShockwaveC2Aero# now in Poland. Join us on 19-20 June at the 2nd Kashubian-Pomeranian Interventional Cardiology Workshop to explore insights from the first Shockwave C2 Aero case in Poland and discuss how this technology is advancing calcium modification in clinical practice. Ready to rethink calcium treatment? Let’s take on the toughest lesions, together. Register now: US Rx only. Safety Info: ​Product availability may vary by country.